A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC

Inclusion Criteria:

1. Signed informed consent form before any trial-related processes;

2. Age ≥18 years;

3. Histologically or cytologically confirmed SCLC;

4. Advanced SCLC who failed first-line platinum-based chemotherapy with or withoutcheckpoint inhibitors;

5. Have adequate organ function;

6. The Eastern Cancer Cooperative Group (ECOG) performance score of 0 or 1;

7. Life expectancy of ≥12 weeks;

8. Had at least one measurable tumor lesion according to RECIST v1.1.

Exclusion Criteria:

1. History of severe allergic disease, severe drug allergy or have known allergy to anycomponent of the study drugs;

2. Evidence and history of severe bleeding tendency;

3. History of severe cardiovascular diseases within 6 months;

4. Current presence of severe superior vena cava syndrome and spinal cord compression;

5. Current presence of uncontrolled pleural, pericardial, and peritoneal effusions;

6. History of allogeneic hematopoietic stem cell transplantation or allogeneic organtransplantation;

7. History of alcohol abuse, psychotropic substance abuse or drug abuse;

8. Human immunodeficiency virus (HIV) infection or known acquired immunodeficiencysyndrome;

9. Pregnant or lactating women;

10. Other conditions considered unsuitable for this study by the investigator.